Akeso
5-FU (5-fluorouracil)(Akeso)은 Non-small Cell Lung Cancer Stage IIIB/IV 표적 치료제로, Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC) 영역에서 개발·상용화 중입니다. 작용기전: inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 41.7% (ClinicalTrials.gov NCT00609622). 차별점: novel biomarkers and targeted strategies.
Non-small Cell Lung Cancer Stage IIIB/IV
Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC)
Recruiting
novel biomarkers and targeted strategies
inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway
t cells to oxaliplatin (L-OHP) and 5-fluorouracil (5FU), an effect that was reversible upon PI3K pathway activation
DNA damage, with etoposide exhibiting the highest tail intensity (~60 %)
biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t
downregulation of PD-L1 via the IL-6/JAK/STAT3 pathway, reduction of immunosuppression, and promotion of immunogenic cell death (ICD)
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Akeso
5-FU (5-fluorouracil)(Akeso)은 Non-small Cell Lung Cancer Stage IIIB/IV 표적 치료제로, Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC) 영역에서 개발·상용화 중입니다. 작용기전: inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 41.7% (ClinicalTrials.gov NCT00609622). 차별점: novel biomarkers and targeted strategies.
Non-small Cell Lung Cancer Stage IIIB/IV
Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC)
Recruiting
novel biomarkers and targeted strategies
inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway
t cells to oxaliplatin (L-OHP) and 5-fluorouracil (5FU), an effect that was reversible upon PI3K pathway activation
DNA damage, with etoposide exhibiting the highest tail intensity (~60 %)
biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t
downregulation of PD-L1 via the IL-6/JAK/STAT3 pathway, reduction of immunosuppression, and promotion of immunogenic cell death (ICD)
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.